W. L. Gore & Associates to Acquire Conformal Medical and Its Investigational CLAAS® AcuFORM™ Left Atrial Appendage Occlusion System

January 5, 2026, Materials Science and Medical Technology Company W. L. Gore & AssociatesAnnounced that it has partnered with the U.S. cardiovascular interventional device companyConformal MedicalReach a final acquisition agreement. According to the announcement, Gore will acquire Conformal Medical and its ongoingCLAAS^®AcuFORM™ Left Atrial Appendage Occlusion System (LAAO)Project. The transaction is expected to be completed in early 2026, subject to regulatory approval, and the transaction amount has not been disclosed.

This is another significant move by Gore in recent years to continuously expand its product portfolio in the cardiovascular and endovascular treatment fields. The company stated that this acquisition will propel it into the adjacent structural heart intervention field and further enrich its existing cardiac and vascular solutions portfolio.

# Clinical Needs: Long-term Challenges in Atrial Fibrillation and Stroke Prevention

Left Atrial Appendage Occlusion (LAAO) is a procedure aimed at Patients with non-valvular atrial fibrillation (AFib)The core goal of interventional treatment methods is to reduce the risk of stroke caused by thrombus formation in the left atrial appendage, thereby reducing or replacing long-term oral anticoagulant therapy.

Atrial fibrillation is one of the most common persistent arrhythmias. According to the American Heart Association, the number of patients with atrial fibrillation in the United States is expected to exceed a certain number by 2030.12 Million CasesIn these patients, a significant portion face issues such as high risk of bleeding from anticoagulant drugs, insufficient compliance, or restrictions on long-term medication, which has gradually drawn attention to one-time interventional treatment solutions.

In clinical practice, LAAO is usually performed through a minimally invasive transcatheter approach but still faces multiple challenges, including significant variations in the anatomical morphology of the left atrial appendage, complex device specifications, high dependence on intraoperative imaging, and resource consumption caused by perioperative anesthesia and hospitalization management. These factors also serve as an important backdrop driving the continuous evolution of next-generation LAAO devices.

# Product Introduction: The Design Concept of CLAAS AcuFORM

Conformal Medical is advancing CLAAS^®AcuFORM™ System, is a product still inInvestigational Device in Clinical Research Phase, and has not yet been approved for commercial use. The system is implanted via a transcatheter approach and is designed to occlude the opening of the left atrial appendage, thereby reducing the risk of thrombus formation.

In terms of structural design, CLAAS AcuFORM adoptsNitinol Inner Frame, combined with Conformal Medical's self-developed Foam Matrix Implant StructureThe company stated that the goal of this structural design is to accommodate a wider range of left atrial appendage anatomical types with fewer product specifications.

According to public information, CLAAS AcuFORM is designed only asTwo specifications, with the aim of simplifying the preoperative evaluation and device selection process. At the same time, the system is designed to reduce reliance on transesophageal echocardiography (TEE), thereby creating conditions for completing the surgery without general anesthesia and promoting the evolution of LAAO towards a "same-day" treatment pathway.

From a technical positioning perspective, CLAAS AcuFORM builds upon the foundational research and development of the earlier CLAAS device by Conformal, continuing the core concept of achieving anatomical conformity and stable occlusion through a foam structure.

# Clinical Progress: From Early Applications to Pivotal Studies

In terms of clinical advancement, Conformal Medical has continuously supported its product development and trial implementation through multiple rounds of financing. The company completed its Series D financing in 2023 and finished another round in August 2025. $32 Million Series D Extension Financing, The funds are mainly used to support itsCONFORM Pivotal Clinical TrialPatient enrollment, as well as subsequent pre-commercialization preparations.

The CONFORM study aims to systematically evaluate the performance of the CLAAS AcuFORM system in terms of safety and effectiveness, and compare it with commercially available LAAO devices, as part of preparations for future submission to the U.S. Food and Drug Administration (FDA).Pre-Market Approval (PMA)Application for Core Clinical Evidence.

Conformal Medical previously disclosed that its next-generation AcuFORM system has beenMore than 100 patientsCompleted the application in China and accumulated preliminary experience in deliverability and safety. Meanwhile, the company also mentioned that its early GLACE study explored the feasibility of completing the procedure under intracardiac echocardiography (ICE) guidance to further reduce reliance on general anesthesia and intubation.

# W. L. Gore & Associates' Accumulation in Cardiovascular and Materials Science

W. L. Gore & AssociatesFounded in 1958, it is a company known for its expertise in materials science. The company has long focused on researching and developing solutions to material engineering challenges in complex environments, with applications of its technology extending from aerospace to the healthcare field.

In the medical business, Gore has been deeply engaged in the fields of cardiac, vascular, and surgical solutions for over 50 years, with related products cumulatively implanted.More Than 50 Million PiecesThe company emphasized that its focus in medical technology innovation has always been on product performance, ease of use, and service quality, while supporting clinical practice through research, education, and quality programs.

Chairman and CEO of W. L. Gore & AssociatesBret SnyderIn this announcement, it was stated that CLAAS AcuFORM represents an innovation direction driven by science and oriented toward clinical value, showing strong synergy with Gore's existing endovascular and cardiac product portfolios. This acquisition is also regarded as an important step for the company to expand into adjacent interventional therapy fields.

# Technology Positioning of Conformal Medical

Conformal MedicalIt is a medical device company focused on the research and development of stroke prevention devices. The company addresses the clinical needs of patients with non-valvular atrial fibrillation and is committed to simplifying the left atrial appendage closure procedure through device innovation.

Conformal Medical's long-term goal is to establish LAAO as aSingle Operator, Completed on the Same DayThe interventional treatment method reduces the dependence of surgery on anesthesia, imaging, and inpatient resources. President and CEO of the companyJames ReinsteinConformal Medical stated that the collaboration with Gore will provide stronger support in technology development, global distribution, and operational aspects, accelerating the product’s progress through clinical and regulatory processes.

# Conclusion: Observations on the Technology and Pathways Behind M&A

Overall, Gore's acquisition of Conformal Medical reflects the common path for large medical technology companies to supplement their innovative pipelines and enter adjacent subfields through mergers and acquisitions in the mature cardiovascular market. As an important technical direction connecting drug treatment with structural heart intervention, LAAO is currently in the phase of evolving from "clinical feasibility" towards "process simplification and scaled application."

As the subsequent clinical research and regulatory progress of the CLAAS AcuFORM system advance, its actual performance in terms of anatomical adaptability, perioperative management, and resource utilization efficiency still awaits further validation through more clinical data. With the platform support from W. L. Gore & Associates, this technical pathway is entering a new phase of development, and its future progress is worth continuous attention.